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OHA and HCV treatment outcomes 717randomized
controlled trial;
sustained virological
responseplus ribavirin (1000e1200 mg/day) or just PR (Arm D; nZ 5). The primary end point was SVR,
and secondary end points were viral clearance at Weeks 17, 29, and 53. There were no differ-
ences among all arms at baseline.
Results: Using intent-to-treat analysis, SVR was observed in 66.7% (4/6), 83.3% (5/6), 66.7% (4/
6), and 60% (3/5) in Arms A, B, C, and D, respectively. SVR was higher in female patients
receiving OHA [90% (9/10)] than in male patients [50% (4/8)]. Results of per protocol analysis
showed that SVR was 80.0% (4/5) in Arm A, 100% (5/5) in Arm B, 66.7% (4/6) in Arm C, and 60%
(3/5) in Arm D. Patients receiving OHA had a higher rapid virologic response: 11/18 (61%) versus
2/5 (40%). Complete early virologic response was comparable between patients receiving OHA
and PR [15/18 (83%) vs. 4/5 (80%)].
Conclusion: Our preliminary data show add-on OHAs to PR might achieve better early viral ki-
netics and SVR. However, further larger studies are needed to confirm these findings.
Copyright ª 2014, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Hepatitis C virus (HCV) infection is the leading cause of liver
diseases and liver transplantation worldwide.1e3 Peginter-
feron alfa plus ribavirin (PR) is the standard choice of
treatment for HCV infection in many parts of the world, but
it is only effective in a certain proportion of chronic hep-
atitis C (CHC) patients.4e6 Because HCV may hijack host
glucose or lipid metabolism to complete its life cycle, in-
terventions on host metabolism may inhibit HCV replication
by affecting its replication complex.7,8 Therefore, modi-
fying metabolic factors becomes a reasonable measure for
the comprehensive management of HCV infection.9
Among the various metabolic factors, insulin resistance
(IR) is known to aggravate hepatic steatosis, drive liver
fibrosis progression, increase the risk of hepatocellular
carcinoma, and is associated with hepatitis C viral load and
poor virologic response of interferon (IFN) in CHC
patients.10e13 Because oral hypoglycemic agents (OHAs)
could improve IR, several studies have examined the ef-
fects of improving IR on the virologic response of IFN by
combining OHA with IFN-based therapy for white patients
with CHC genotype 1 and IR.14 Although Taiwanese patients
have a better response to IFN-based therapy than white
patients,15 whether an add-on OHA to PR benefits Taiwa-
nese CHC patients remains unknown.
To this end, we conducted a prospective, randomized
pilot trial on 23 consecutive patients with genotype 1 CHC
infection and IR, and examined the impact of add-on OHA
to PR on the virologic responses of these patients.Patients and methods
HCV group
Eligible patients were those who were 20 years of age or
older, chronically infected with HCV genotype 1, and naı¨ve
to IFN treatment and other experimental antiviral or
immunosuppressive therapy. All patients had antibodies to
HCV and a quantifiable serum HCV RNA for more than 6
months, abnormal serum alanine aminotransferase (ALT)
levels, and a homeostasis model assessment of IR (HOMA-IR)index  2 (Table 1). Liver biopsy was not considered
mandatory for study inclusion. The enrollment for this
study started in May 2009, and the trial ended in December
2011. Exclusion criteria were a neutrophil count <1500/
mm3, a platelet count <90,000/mm3, a hemoglobin level
<12 g/dL for women and <13 g/dL for men, positive for
hepatitis B surface antigen or human immunodeficiency
virus antibody, alcohol intake >20 g/day, a known history
or serological evidence of autoimmune liver disease,
inheritable disorders such as hemochromatosis or Wilson’s
disease, diabetes mellitus or under OHA therapy, liver
cirrhosis, renal insufficiency, malignancy, and the presence
of drug abuse, chronic disease, psychiatric disease, or
pregnancy and lactation.Study design
This was a prospective, multicentered, randomized, open-
label controlled trial (registered in ClinicalTrials.gov; No.
NCT01025765). The study was conducted in three academic
centers. All sites received approval from their respective
ethics committees. Each patient provided written informed
consent for participation. Patients were randomly assigned
in a 1:1:1:1 ratio to receive acarbose 50 mg/day for the 1st
month and 50 mg/meal from Week 5 to 12 (Arm A; n Z 6),
metformin 500 mg for the 1st month and 500 mg three times
daily from Week 5 to 12 (Arm B; nZ 6), pioglitazone 15 mg/
day for the 1st month and 30 mg from Week 5 to 12 (Arm C;
n Z 6), or under observation for the 1st 3 months (Arm D;
n Z 5) and received peginterferon alfa-2b (PEG-Intron;
Schering-Plough Inc., Kenilworth, NJ, USA) at a dose of
1.5 mg/kg of body weight weekly plus oral ribavirin (Rebe-
tol; Schering-Plough Inc.) at a dose of 1000 mg (for those
with body weight < 75 kg) or 1200 mg (for those with a body
weight  75 kg) daily from Week 5 to 52 (Fig. 1). Partici-
pants were assessed on an outpatient basis at Weeks 5, 9,
13, 17, 29, 41, and 53 during treatment and followed every
12 weeks for 24 weeks after discontinuation of treatment to
confirm sustained virological response (SVR). Treatment
was discontinued in patients who did not achieve an early
virological response (EVR) at Week 17 or were HCV RNA
positive at Week 29.
Table 1 Baseline characteristics of chronic hepatitis C patients receiving OHA plus Peg-IFN/RBV therapy.
Case no. Age Sex HOMA-IR Treatment Body
weight
(kg)
ALT
(U/L)
HCV RNA
(log10 IU/mL)
PLT
(K/mL)
Tbil AC-sugar Insulin CHO TG RVR EVR EOTR SVR
1 51.2 M 4.4 Pioglitazone 64 137 5.65 311 0.46 90 20.0 200 215 0 1 0 0
7 31.5 F 2.3 Pioglitazone 43 53 5.65 156 0.49 90 10.5 143 45 0 1 1 1
14 51.5 M 2.0 Pioglitazone 66.2 48 6.40 206 0.95 98 8.3 188 74 0 pEVR 1 0
15 44.5 M 2.1 Pioglitazone 65 76 6.20 137 1.03 92 9.3 247 118 1 1 1 1
17 55.9 F 3.4 Pioglitazone 54 110 5.01 106 1.58 108 12.6 215 133 1 1 1 1
19 66.5 F 2.7 Pioglitazone 56 19 4.56 143 0.78 109 10.0 174 187 1 1 1 1
2 72.6 F 3.7 Metformin 74 117 4.33 178 1.3 104 14.6 130 76 1 1 1 1
10 54.4 M 4.9 Metformin 65.2 120 6.34 173 0.67 136 14.7 120 70 0 0 0 0
12 61.9 F 4.0 Metformin 67 96 6.24 187 0.57 92 17.6 173 156 1 1 1 1
20 61.9 F 2.1 Metformin 59 97 6.13 219 0.79 92 9.3 193 86 0 1 1 1
16 49.7 M 4.0 Metformin 72 75 6.25 155 1.02 126 12.8 167 334 1 1 1 1
18 67.8 M 3.5 Metformin 71 57 6.97 114 0.8 111 12.7 107 205 0 1 1 1
5 56.6 F 3.4 Acarbose 54.5 123 5.77 221 0.38 88 15.8 179 111 1 1 1 1
6 36.8 F 4.3 Acarbose 62.8 198 4.51 238 0.531 89 19.5 174 109 1 1 1 1
8 56.4 F 5.0 Acarbose 75.7 67 6.57 130 0.58 95 21.2 175 61 1 pEVR 1 1
11 36.9 M 5.1 Acarbose 76.4 92 7.74 252 0.84 109 19.1 189 108 0 1 0 0
13 58.0 F 3.8 Acarbose 54 97 4.66 143 0.58 105 14.5 166 65 1 1 1 0
3 43.1 M 2.1 Acarbose 80.4 227 6.27 211 0.73 80 10.5 146 90 1 1 1 1
9 54.2 M 3.7 Control 73.5 71 6.95 139 0.61 99 15.1 176 63 1 1 1 1
4 41.1 M 3.1 Control 75.7 112 5.57 241 0.421 92 13.6 133 41 1 1 1 1
21 64.2 F 2.7 Control 49 43 5.92 265 1.22 150 7.2 207 90 0 1 1 0
22 62.7 F 6.3 Control 89 97 6.95 132 1.09 103 24.6 178 161 0 pEVR 1 0
23 46.7 M 3.9 Control 83 31 7.04 183 0.95 115 13.7 179 73 0 1 1 1
Homeostasis model assessment of insulin resistance (HOMA-IR) Z [fasting insulin (mU/L)  fasting glucose (mg/dL)  0.05551/22.5].
For virologic response (SVR, EVR, EOTR, and RVR), Yes Z 1 and No Z 0.
ACZ ante cibum; ALTZ alanine aminotransferase; CHOZ total cholesterol; EOTRZ end-of-treatment response; EVRZ early virologic
response; HCV Z hepatitis C virus; OHA Z oral hypoglycemic agents; Peg-IFN Z pegylated interferon; pEVR Z partial early virologic
response; PLTZ platelet count; RBVZ ribavirin; RVRZ rapid virologic response; SVRZ sustained virologic response; TbilZ bile total
bilirubin; TG Z triglyceride.
718 C.-S. Hsu et al.Ethical considerations
The study was conducted in accordance with the principles
of the Declaration of Helsinki, and the study protocol was
approved by the Ethics Committee of each study site.
Data collection and laboratory analyses
Data on sex, age, body mass index (BMI), serum fasting
blood glucose, triglyceride (TG), total cholesterol (CHO),
low-density lipoprotein (LDL), high-density lipoprotein
(HDL), and ALT levels were collected. BMI was calculated as
weight in kilograms divided by height in square meters.
Blood samples were collected in the morning after 12-hour
fasting and were measured by standard laboratory tech-
niques. Serum fasting blood glucose, TG, CHO, LDL, HDL,
and ALT levels were measured using an autoanalyzer
(Hitachi 7250, Special; Hitachi, Tokyo, Japan). An upper
limit of normal serum ALT levels was set at 30 U/L for men
and 19 U/L for women.16,17 Serum insulin was measured
using an immunometric assay (IMMULITE; Diagnostic Prod-
ucts Co., Los Angeles, CA, USA). HBsAg, anti-HCV, and
antihuman immunodeficiency virus were assayed using
commercial kits (Abbott Laboratories, Chicago, IL, USA).The IR index was determined using HOMA-IR model [HOMA-
IR Z fasting insulin (mU/L)  fasting glucose (mg/
dL)  0.05551/22.5] as previously described.18,19 Serum
HCV RNA was measured using a standardized automated
qualitative reverse transcription polymerase chain reaction
assay (COBAS TaqMan HCV Test v2.0). The detection limit
was 25 IU/mL. HCV genotyping was performed with the use
of a hybridization technique (INNO-LiPA HCV; Innogenetics,
N.V., Zwijnaarde, Belgium).Efficacy assessments
The primary end point was SVR. The secondary end points
were viral clearance (HCV RNA < 25 IU/mL) at Weeks 17,
29, and 53. Rapid virologic response (RVR) was defined if an
undetectable serum HCV RNA level at Week 9 was achieved.
EVR was defined as an undetectable serum HCV RNA level or
at least a two-log decrease of the baseline HCV RNA level at
Week 17. Complete EVR (cEVR) was defined as undetect-
able serum HCV RNA at Week 17 of therapy, and partial EVR
(pEVR) as at least a two-log reduction of serum HCV RNA
from baseline to Week 17 of therapy. Virologic responder
was defined as those having RVR or EVR. SVR was defined as
an undetectable serum HCV RNA level (<25 IU/mL) at 24
23 Patients consecutively enrolled 
(Arm C; n = 6)
Pioglitazone 15 mg/d 1st mo  
+  30 mg/day 
from Week 5 to 12
(Arm B; n = 6) 
Metformin 500 mg/d 1st mo + 
500 mg x 3 daily
from Week 5 to 12
(Arm A; n = 6)
Acarbose 50 mg/d 1st mo +  
50 mg/meal
from Week 5 to 12
1:1:1:1  randomization
(arm D; n = 5)
Peg-IFN alfa-2b 1.5 μg 
/kg/wk
+ RBV (1000 mg/d for 
<75 kg or 1200 mg/d 
for ≥75 kg) 
from Week 5 to 52. 
Complete treatment and 
follow up (n = 5)
Complete treatment and 
follow up (n = 5)
Complete treatment and 
follow up (n = 6)
Complete treatment and 
follow up (n = 5)
Adverse event 
and 
discontinued 
treatment (n = 1)
Adverse event 
and 
discontinued 
treatment (n =1)
Figure 1 Study flow. Peg-IFN Z pegylated interferon; RBV Z ribavirin.
OHA and HCV treatment outcomes 719weeks after the discontinuation of treatment.20,21 Virolog-
ical breakthrough was defined as a detectable HCV RNA
level during treatment in patients who had undetectable
HCV RNA at Week 29. Virological relapse was defined as a
detectable HCV RNA level during follow up in patients who
had undetectable HCV RNA at Week 53.
Safety assessments
Adverse events were recorded and assessed on an outpa-
tient basis by clinical examinations and laboratory tests at
Weeks 5, 9, 13, 17, 29, 41, 53, and 77. Stepwise reductions
of PR were permitted in managing clinically significant
adverse events, or laboratory abnormalities recorded.
Statistical analysis
Patients who dropped out of the trial were classified as
not having a virologic response, and the analyses included
all randomized patients for whom outcome data were
available. Categorical data were presented as percent-
ages, whereas continuous data were presented as mean
with standard deviations. Log transformation was per-
formed for variables with a significant deviation from
normal distribution. Differences in baseline characteris-
tics among the arms were assessed using Chi-square test
with Yates’s correction for discrete variables. We
compared the virological response of patients in each arm
with the ones receiving PR (Arm D) at Weeks 9, 17, and 77.
Linear regression and multivariate analyses using logistic
regression were performed to examine the associations of
add-on OHA, SVR, and various clinical factors. All analyses
were performed using Stata statistical software (version
8.0; Stata Corp., College Station, TX, USA). All tests were
two sided and p < 0.05 was considered statistically
significant.Results
Baseline characteristics of patients among different
treatments
A total of 23 patients were consecutively recruited and
randomly assigned into four different treatment groups and
received at least one dose of medication; two patients
were excluded from per protocol analysis (PPA) because of
not receiving complete treatment and follow up after
enrollment [one patient in the acarbose group (Arm A, Case
11) discontinued treatment at Week 28 because of hyper-
thyroidism, and the other patient in the metformin group
(Arm B, Case 10) discontinued treatment at Week 13
because of vertigo after a peginterferon alfa injection].
The four treatment groups were comparable in terms of
age, sex, and other variables measured on entry into the
trial (Table 1).Virological responses among different treatment
groups
In the intent-to-treat analysis, SVR was observed in 66.7%
(4/6), 83.3% (5/6), 66.7% (4/6), and 60% (3/5) in Arms A, B,
C, and D, respectively. In the PPA, SVR was 80.0% (4/5) in
Arm A, 100% (5/5) in Arm B, 66.7% (4/6) in Arm C, and 60%
(3/5) in Arm D. Patients with SVR had lower IR than those
without. Females receiving add-on OHA [90% (9/10)] had a
higher SVR than males [50% (4/8)].
RVR was 100% (5/5) in Arm A, 60% (3/5) in Arm B, 50% (3/
6) in Arm C, and 40% (2/5) in Arm D. Add-on OHA to PR
increased the RVR [Arms A þ B þ C vs. D: 11/18 (61%) vs. 2/
5 (40%)].
All patients attained EVR, and one patient in Arm A, one
in Arm C, and one in Arm D had pEVR. Add-on OHA to PR did
not change the cEVR [15/18 (83%) vs. 4/5 (80%)].
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receiving add-on OHA [11.1% (2/18) vs. 40% (2/5)]. Among
the four patients with virological breakthrough, one in Arm
A was male, and the other three were female (Table 1).
Safety
The most common adverse events were anemia, fever,
gastrointestinal upsets, headache, skin rash, itching, and
cough, which were similar to reports from previous trials of
IFN-based therapy. Three patients experienced hyperthy-
roidism during therapy (Cases 6, 7, and 11) and one dis-
continued medication (Case 11). Two patients experienced
vertigo (Cases 10 and 13) and one discontinued treatment
(Case 10). Among patients who received pioglitazone in Arm
C, one had pancreatitis (Case 14) and another one had
pancytopenia (Case 3). One patient who received acarbose
in Arm A experienced hyperglycemia and hyperlipidemia
during the therapy (Case 5). All these patients recovered
after supportive treatment and reductions in the doses of
peginterferon alfa-2b or ribavirin administered. No signifi-
cant side effects were observed during the period when
patients received add-on OHA.
Discussion
IR is known to affect SVR of CHC patients.22 Several proof-
of-concept trials with different pharmacological in-
terventions aiming at reducing IR in CHC patients have
shown the improvement of hepatitis treatment out-
comes,11,12,14,23 but the optimal modality, treatment
schedule, and the applicability to different ethnicity and
HCV genotypes remain unclear. In this pilot study, we
examined the virological effects of different OHAs (piogli-
tazone, metformin, and acarbose) on CHC patients with
HOMA-IR  2, and found that add-on OHAs to PR may
improve RVR and SVR in these difficult-to-treat Asian pa-
tients. Our results echo previous reports14,23 and indicate
that short-term OHAs might be beneficial to the virological
response of CHC patients.
In this study, two patients discontinued treatment
because of adverse events and withdrew from the study,
but none of these adverse events were attributed to OHAs.
One patient in the metformin group (Arm B, Case 10) dis-
continued her treatment at Week 13 because of vertigo
after peginterferon injection, and the other one in the
acarbose group (Arm A, Case 11) withdrew at Week 28
because of hyperthyroidism. The remaining patients who
received add-on OHAs completed treatment and follow up,
and none of them had significant side effects during the
period of add-on OHA therapy. Therefore, a combination of
OHAs and PR is safe to CHC patients. In addition, previous
reports demonstrated a better virological response in fe-
male CHC patients receiving add-on OHA therapy.14 We also
observed a trend of increasing SVR in female patients
receiving add-on OHA to PR, although the difference did
not reach a statistical significance, which could be attrib-
utable, at least in part, to a type 2 error in small sample
size.
This study had a few limitations. First, the sample size is
relatively small, hence it is not powerful enough to detectsignificant improvements of virologic response in patients
receiving add-on OHA therapy. However, the trends shown
in this study were comparable with reports from other
groups. Therefore, our results might imply that this proof-
of-concept approach could work in Asian CHC patients. To
detect significant differences between groups, a larger
study including at least 140 patients in each study arm is
needed in the future. Second, because most patients
attained EVR in this study and patients receiving add-on
OHA had a higher RVR than PR controls, it seemingly implies
that OHAs might affect patients’ viral kinetics in the
beginning. Further studies to examine detailed impacts of
OHAs on viral kinetics are needed. Of note, an 8-week use
instead of a 48-week use of OHA in this study not only de-
creases additional adverse effects and cost, but also high-
lights that the first 8 weeks of OHA therapy might be the
key to improving IR in CHC patients. Future studies are
needed to examine the efficacy of OHA with different
combinations, time series, and dosage. Third, IL28B poly-
morphism is an important and well-known therapeutic
predictor for CHC patients receiving IFN-based therapy.
Because the association of IL28B polymorphism and HCV
was identified in 2009, which is after the implementation of
this study, IL28B polymorphism was not included in this
study. However, according to our previous data, most
Taiwanese CHC patients have the favorable IL28B genotype
contributing to better responses to IFN-based therapy (i.e.,
rs8099917 TT genotype).24,25 Therefore, knowing the dis-
tribution of IL28B genotypes in our patients might not
significantly change our major conclusions. However, future
studies examining the effects of IL28B genotypes on the
therapeutic efficacy of adding OHA in CHC patients are still
needed. Finally, because of the high therapeutic efficacy of
direct acting antiviral (DAA)-based therapy, the value of
insulin sensitizer would be limited in the era of DAA-based
therapy. However, as most Asian countries cannot afford
the price of DAA-based therapy, insulin sensitizer might be
a good alternative for CHC patients in low-income areas. By
contrast, considering the IR-prone feature of HCV and
increased stroke and cardiovascular disease (CVD) risks in
CHC patients,26 adding insulin sensitizer may not only
benefit CHC patients who have increased IR before IFN-
based therapy, but also potentially decrease stroke and
CVD risks in most CHC patients. However, future studies
examining the effects of insulin sensitizer on stroke and
CVD risks of CHC patients receiving IFN-based therapy are
awaited.
In summary, our preliminary data show the promising
results of add-on OHAs to PR for the treatment of Asian CHC
patients. Considering the lower cost, better safety, and
greater accessibility of OHAs, further larger proof-of-
concept studies are anticipated.Author contributions
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